Technology platforms

Heat shock proteins
Antigenics’ core technology is based on heat shock proteins, a ubiquitous class of proteins involved in generating immune response. HSP technology is being applied in both patient-specific and off-the-shelf treatment settings.   White paper: Heat Shock Proteins' Vaccine Potential

QS-21™ immune adjuvant
The QS-21 adjuvant has the potential ability to increase total vaccine-specific antibody response and T-cell response.   White paper: Advent of the Adjuvant